Positron Emission Tomography (PET) study
Study identifier:D1950C00004
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An Open-label Positron Emission Tomography (PET) Study using 2 [18F] F A85380 to determine α4β2 Neuronal Nicotinic Receptor (NNR) Occupancy of AZD1446 After Oral Administration to Male and Non-fertile Female (non-nicotine users) Healthy Volunteers
Medical condition
Healthy
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD1446
Sex
All
Actual Enrollment
11
Study type
Interventional
Age
20 Years - 45 Years
Date
Study Start Date: 01 Apr 2009
Primary Completion Date: 01 Aug 2009
Study Completion Date: 01 Aug 2009
Study design
Allocation: Non-randomized
Endpoint Classification: Pharmacokinetics/dynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verification:
Verified 01 Jul 2014 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 2-[18F]-F-A85380 Single microdose | Radiation: 2-[18F]-F-A85380 iv, single dose |
| Experimental: AZD1446 Single oral administration | Drug: AZD1446 Solution, oral, single dose |
Contacts
Investigators
Principal Investigator
Björn Paulsson
AstraZeneca Södertälje
